Steatotic Liver Disease (SLD) is defined as excessive built-up of fat in the liver (>5 %) diagnosed by imaging or a liver biopsy [1]. Recently, a novel term metabolic dysfunction-associated steatotic liver disease (MASLD) has been introduced in the medical field, to describe patients with liver steatosis, who also present with at least one of the following five cardiometabolic risk factors: obesity, diabetes or impaired glucose regulation, hypertension, hypertriglyceridemia, and low high-density lipoprotein (HDL) cholesterol [2].
